CXCR1 and breast cancer: In the same work reparixin (formerly repertaxin), a powerful small molecular weight CXCR1 inhibitor, was tested in several NOD/SCID mice breast cancer models showing that selective targeting of CXCR1 may effectively reduce in vivo the tumour-initiating population and that the combination of reparixin and docetaxel, one of the most effective chemotherapeutic currently available for the treatment of breast cancer patients, resulted in a concomitant reduction of the bulk tumour mass and CSC population.